Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: IDIS deal

IDIS deal 12 Jan 2016 06:47 #5978

  • Joncon63
  • Joncon63's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 90
  • Thank you received: 6
finance.yahoo.com/news/cytori-enters-agreement-idis-launch-120000755.html

Does this mean no partner in Europe for Scleroderma? No up-front cash?
Or does this sweeten the pot for a partner?

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 07:23 #5980

  • CalhounDoppelganger
  • CalhounDoppelganger's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 160
  • Thank you received: 20
Seems like strategic play to entice a partner but ultimately ....no $ equates to fluff.

If this is the only announcement today then we're lucky if the share price hits $0.22

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 07:37 #5981

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 388
  • Thank you received: 196
This does not preclude a partnership deal for Scleroderma. However, I do not think they want to give away the indication for peanuts hence this deal. Lets not forget that if successful in scleroderma it opens up the way to the whole auto immune space, eg RA, MS etc

This development does seem to indicate that there may well be sufficient demand on a self pay basis that warrants accessing it via the compassionate use, expanded access route.

As per IDIS website :

As the global leaders and specialists in Managed Access Programs (MAPs), we develop ethical and regulatory compliant strategic solutions for pharmaceutical and biotechnology companies enabling a fast and efficient response to patient demand outside of traditional access routes. This means patients get the lifeline they need, and other stakeholders gain the reassurance they require.
Also known as expanded access, named patient, temporary authorization for use, compassionate use, and early access, these terms encompass a variety of different regulatory approaches which are all designed to provide access to medicines not available to patients via the traditional access route. This could be at a number of different stages during the product lifecycle.
The benefits of implementing a MAP are significant, not just for patients and healthcare professionals who have run out of treatment options, but for the pharmaceutical and biotechnology companies that hold the products that could help.

Scleroderma is an Orphan Indication that is well suited to the above distribution pathway. Also I do not imagine that they would have announced this unless the STAR & SCLEREDAC trials had been fully or almost fully enrolled.

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 08:10 #5983

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3362
  • Thank you received: 1116
Some follow up information in these slides---






Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

IDIS deal 12 Jan 2016 08:18 #5984

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 903
  • Thank you received: 148
Its simply a early access bridge for patients to obtain the therapy. However, it appears to be private pay unless some institution finances the procedures. No mention of such. BTW, they had a typo on page 28 showing that OA data would be released in 2015!! Not good the present a typo on such critical information in front of #JPM2016. I sent Marc an email. Hopefully they fix.

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 10:54 #5993

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2868
  • Thank you received: 204
WST...I read it as private pay or with help from various institutions for those who need it.

Partner (should one emerge) likely some time away imho

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 11:06 #5994

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 903
  • Thank you received: 148
Hedge, I got an answer. Something that should have been mentioned in the release:

"Reimbursement via combination of government, hospitals, insurance etc".

I think that is important news that should have been mentioned up front.
The following user(s) said Thank You: Joncon63

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 11:08 #5995

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2868
  • Thank you received: 204
WST

Right...sorta in there...agree not real clear

Please Log in or Create an account to join the conversation.

IDIS deal 12 Jan 2016 11:16 #5996

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3362
  • Thank you received: 1116
The first slide indicates as Objective Number 4 :

Implement a chargeable program where regulations allow

That wording is somewhat confusing, since surely something or somebody is to be charged- however I am sure they do not mean the patient, but certain institutions. I do know for instance for sure, that a reimbursement possibility exists in Germany through hospital exemptions and other advanced regulations on the use of new medical technology and therapies.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.882 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites